Novavax (NVAX) Receivables (2010 - 2026)

Novavax's Receivables history runs 15 years deep, the most recent figure standing at $27.5 million for Q1 2026.

• On a quarterly basis, Receivables fell 52.8% year-over-year to $27.5 million in Q1 2026; TTM through Mar 2026 was $27.5 million, a 52.8% decrease from a year earlier, with the FY2025 full-year figure at $117.2 million, down 3.39% from the prior year.
• Receivables fell to $27.5 million in Q1 2026 per NVAX's latest filing, from $106.4 million in the prior quarter.
• Across five years, Receivables topped out at $530.5 million in Q1 2022 and bottomed at $27.5 million in Q1 2026.
• The 5-year median for Receivables is $124.8 million (2022), against an average of $174.3 million.
• Across the five-year window, Receivables plunged 90.91% in 2024 and soared 468.85% in 2025, its largest moves.
• Year by year, Receivables stood at $124.8 million in 2022, then surged by 152.96% to $315.7 million in 2023, then plunged by 63.99% to $113.7 million in 2024, then fell by 6.41% to $106.4 million in 2025, then plunged by 74.14% to $27.5 million in 2026.
• Per Business Quant, the three latest NVAX Receivables figures stand at $27.5 million (Q1 2026), $106.4 million (Q4 2025), and $47.0 million (Q3 2025).